Kaken Pharmaceutical Co., Ltd. (4521) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Sumitomo Pharma Co., Ltd.

Tsumura & Co.

Suzuken Co., Ltd.

Nippon Shinyaku Co., Ltd.

Santen Pharmaceutical Co., Ltd.

Hisamitsu Pharmaceutical Co., Inc.

JCR Pharmaceuticals Co., Ltd.

Kobayashi Pharmaceutical Co., Ltd.

SAWAI GROUP HOLDINGS Co., Ltd.

Kaken Pharmaceutical Co., Ltd.

Taisho Pharmaceutical Holdings Co., Ltd.

Why is Kaken Pharmaceutical Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 1.05% and Operating profit at -4.77% over the last 5 years

With a fall in Net Sales of -25.82%, the company declared Very Negative results in Dec 25

The company has declared negative results in Mar 25 after 2 consecutive negative quarters
INTEREST(HY) At JPY 22 MM has Grown at 57.14%
NET SALES(Q) At JPY 18,261 MM has Fallen at -25.82%
PRE-TAX PROFIT(Q) At JPY 559 MM has Fallen at -91.06%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -11.68%, its profits have risen by 80.1% ; the PEG ratio of the company is 0.2
At the current price, the company has a high dividend yield of 0

Below par performance in long term as well as near term

Along with generating -11.68% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Kaken Pharmaceutical Co., Ltd. for you?

Low Risk, High Return

Absolute

Risk Adjusted

Volatility

Kaken Pharmaceutical Co., Ltd.

-100.0%

1150.50

20.37%

Japan Nikkei 225

38.94%

1.30

28.24%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

1.05%

EBIT Growth (5y)

-4.77%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.43

Sales to Capital Employed (avg)

0.54

Tax Ratio

28.25%

Dividend Payout Ratio

52.00%

Pledged Shares

Institutional Holding

0.10%

ROCE (avg)

20.37%

ROE (avg)

7.98%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.14

EV to EBIT

5.17

EV to EBITDA

4.60

EV to Capital Employed

1.24

EV to Sales

1.14

PEG Ratio

0.15

Dividend Yield

0.03%

ROCE (Latest)

24.03%

ROE (Latest)

9.49%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company

NO KEY POSITIVE TRIGGERS

-40What is not working for the Company

INTEREST(HY)

At JPY 22 MM has Grown at 57.14%

NET SALES(Q)

At JPY 18,261 MM has Fallen at -25.82%

PRE-TAX PROFIT(Q)

At JPY 559 MM has Fallen at -91.06%

NET PROFIT(Q)

At JPY 386.68 MM has Fallen at -91.42%

ROCE(HY)

Lowest at -2.55%

RAW MATERIAL COST(Y)

Grown by 17.63% (YoY

CASH AND EQV(HY)

Lowest at JPY 102,942 MM

DEBT-EQUITY RATIO (HY)

Highest at -28.8 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.86 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.64 times

Here's what is working for Kaken Pharmaceutical Co., Ltd.

Depreciation

Highest at JPY 837 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (JPY MM)

Here's what is not working for Kaken Pharmaceutical Co., Ltd.

Interest

At JPY 22 MM has Grown at 57.14%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Sales

At JPY 18,261 MM has Fallen at -25.82%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (JPY MM)

Pre-Tax Profit

At JPY 559 MM has Fallen at -91.06%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (JPY MM)

Net Profit

At JPY 386.68 MM has Fallen at -91.42%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (JPY MM)

Cash and Eqv

Lowest at JPY 102,942 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at -28.8 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 1.86 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 2.64 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Raw Material Cost

Grown by 17.63% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales